Verona Pharma (NASDAQ: VRNA)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | -0.400 | 0.0700 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Verona Pharma (NASDAQ: VRNA) through any online brokerage.
Other companies in Verona Pharma’s space includes: Aerie Pharmaceuticals (NASDAQ:AERI), WAVE Life Sciences (NASDAQ:WVE), CymaBay Therapeutics (NASDAQ:CBAY), ANI Pharmaceuticals (NASDAQ:ANIP) and Provention Bio (NASDAQ:PRVB).
The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by Wedbush on Friday, June 17, 2022. The analyst firm set a price target for 18.00 expecting VRNA to rise to within 12 months (a possible 329.59% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Verona Pharma (NASDAQ: VRNA) is $4.19 last updated June 30, 2022, 8:00 PM UTC.
There are no upcoming dividends for Verona Pharma.
Verona Pharma’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Verona Pharma.
Verona Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.